A recent poll highlights growing interest in host response testing for sepsis. Immunexpress CEO Rollie Carlson discusses the findings and the future of rapid diagnostics.
Researchers develop PIPscore using plasma proteomics to identify triple-negative breast cancer patients most likely to benefit from immunotherapy treatment.
The Alzheimer's Association released its first clinical practice guideline on the use of blood-based biomarker tests.
Dana-Farber Cancer Institute, Boston Children's Hospital, and Broad Clinical Labs form BrightSeq collaborative to develop novel clinical diagnostic assays for rare pediatric cancers.
Clinical labs help drive early HIV detection and support efforts to prevent its spread.
At ADLM 2025, researchers spotlight diagnostic innovations that aim to improve gynecologic cancer detection through greater access and less invasive methods.
rex Laboratories has launched BiomeBurden, a comprehensive test that evaluates immune responses to microbial, yeast, and mold triggers.
Lipoprotein(a), or Lp(a), is a genetically determined and under-recognized cardiovascular disease risk factor.
ALZpath pTau217 antibody data was included in 37 submissions at AAIC, building on research demonstrating its sensitivity and accuracy in blood-based tests for Alzheimer's disease.
It's essential to integrate point-of-care testing devices cautiously alongside traditional laboratory tests to ensure robust diabetes management.
With the acquisition, Quest will now provide dialysis lab testing for independent clinics that were previously served by Spectra Laboratories.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A multicenter study found that early sepsis risk testing at triage led to more ED discharges and lower inpatient bed use without compromising patient safety.